Comparative Pharmacology
Head-to-head clinical analysis: IMPOYZ versus TURQOZ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IMPOYZ versus TURQOZ.
IMPOYZ vs TURQOZ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
IMPOYZ is a monoclonal antibody that binds to and inhibits the activity of interleukin-23 (IL-23), a cytokine involved in inflammatory and immune responses. By blocking IL-23, it reduces the production of pro-inflammatory cytokines and attenuates the inflammatory cascade.
TURQOZ is a selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the central nervous system by inhibiting the reuptake of serotonin at the synaptic cleft, leading to increased serotonin levels.
100 mg orally twice daily
400 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life 6–8 hours in adults with normal renal function; prolonged to 15–30 hours in severe renal impairment (CrCl <30 mL/min).
Terminal half-life 12-15 hours; prolonged in renal impairment (up to 30 hours) requiring dose adjustment
Primarily renal (70–80% as unchanged drug via glomerular filtration and tubular secretion); biliary/fecal (15–20%) with minor hepatic metabolism.
Primarily renal (80% unchanged) with 10% fecal, 5% biliary, 5% other
Category C
Category C
Unknown
Unknown